Drug data last refreshed 17h ago · AI intelligence enriched 1w ago
CLINDAGEL is a topical antibiotic gel containing clindamycin phosphate, approved in 2000 for treating bacterial skin infections, particularly acne vulgaris. The drug works by inhibiting bacterial protein synthesis to reduce pathogenic colonization on the skin. It is applied directly to affected areas, offering localized therapeutic effects with minimal systemic absorption.
Declining market presence with minimal Part D utilization signals a mature, contracted franchise with reduced team investment and limited growth opportunities.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clindamycin Phosphate, Adapalene, and Benzoyl Peroxide Triple Combination Gel in Canadian Patients With Acne Vulgaris
Perimenstrual Acne With Clindamycin Phosphate and Benzoyl Peroxide
A Efficacy and Safety of Duac™Compared With Clindamycin Phosphate Gel in the Treatment of Mild to Moderate Acne Vulgaris
W0265-104: A Single-Center, Evaluator-Blinded, Randomized, Placebo-Controlled, Phase 1 Clinical Trial Evaluating the Photoallergic Potential of Topically Applied Clindamycin Phosphate 1.0% and Tretinoin 0.025% (CT Gel) in Healthy Volunteers
Worked on CLINDAGEL at Bausch + Lomb? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
CLINDAGEL positions offer limited growth trajectory and typically involve managing commercial wind-down, generic transition, and cost optimization rather than brand building. Roles on this product are suitable for early-career professionals seeking experience in mature-stage franchise management or mid-career professionals transitioning to generic/OTC strategies.
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/mo